Introduction: Microdosing is an approach to early drug development where exploratory pharmacokinetic data are acquired in humans using inherently safe sub-pharmacologic doses of drug. The first publication of microdose data was 10 years ago and this review comprehensively explores the microdose concept from conception, over the past decade, up until the current date. Areas covered: The authors define and distinguish the concept of microdosing from similar approaches. The authors review the ability of microdosing to provide exploratory pharmacokinetics (concentration-time data) but exclude microdosing using positron emission tomography. The article provides a comprehensive review of data within the peer-reviewed literature as well as the lat...
The process of early clinical drug development has changed little over the past 20 years despite an ...
The development of new drugs for life threatening diseases is an expensive, risky and time-consuming...
Non-linearities occur no more frequently between microdose and therapeutic dose studies than in ther...
INTRODUCTION: Microdosing is an approach to early drug development where exploratory pharmacokinetic...
Introduction: Microdosing is an approach to early drug development where exploratory pharmacokinetic...
The concept of microdosing has been around for approximately 10 years. In this time there have been ...
Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-...
Background: Microdosing studies (human Phase 0) are used to select drug candidates for Phase I clini...
The concept of microdosing has been around for more than a decade. It consists of the subpharmacolog...
Microdosing, or human phase 0 clinical trials, is a technique whereby subpharmacological doses of pr...
Drug development pipelines are plagued by increasing costs and decreasing productivity, so technique...
The use of microdose pharmacokinetic studies as an essential tool in drug development is still to ca...
Microdosing provides a tool to enhance drug development by initiating human studies prior to Phase I...
A decreasing number of new therapeutic drugs reaching the clinic has led to the publication of regul...
Drug development is an activity that is long, complex and expensive. In 2004, attrition in the drug ...
The process of early clinical drug development has changed little over the past 20 years despite an ...
The development of new drugs for life threatening diseases is an expensive, risky and time-consuming...
Non-linearities occur no more frequently between microdose and therapeutic dose studies than in ther...
INTRODUCTION: Microdosing is an approach to early drug development where exploratory pharmacokinetic...
Introduction: Microdosing is an approach to early drug development where exploratory pharmacokinetic...
The concept of microdosing has been around for approximately 10 years. In this time there have been ...
Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-...
Background: Microdosing studies (human Phase 0) are used to select drug candidates for Phase I clini...
The concept of microdosing has been around for more than a decade. It consists of the subpharmacolog...
Microdosing, or human phase 0 clinical trials, is a technique whereby subpharmacological doses of pr...
Drug development pipelines are plagued by increasing costs and decreasing productivity, so technique...
The use of microdose pharmacokinetic studies as an essential tool in drug development is still to ca...
Microdosing provides a tool to enhance drug development by initiating human studies prior to Phase I...
A decreasing number of new therapeutic drugs reaching the clinic has led to the publication of regul...
Drug development is an activity that is long, complex and expensive. In 2004, attrition in the drug ...
The process of early clinical drug development has changed little over the past 20 years despite an ...
The development of new drugs for life threatening diseases is an expensive, risky and time-consuming...
Non-linearities occur no more frequently between microdose and therapeutic dose studies than in ther...